Table 1.
General characteristics of the study groups.
| Control, n, 25 | 5-FU, n, 18 | p | |
|---|---|---|---|
| Age, years | 52.8 ± 15.0 | 52.9 ± 14.0 | 0.9 |
| Gender (Female/Male) | 19/7 | 10/7 | 0.5 |
| Follow-up period | 14.5 ± 3.3 | 13.1 ± 1.8 | 0.1 |
| Lens status (Phakic/Pseudophakic/Aphakic) | 18/4/4 | 11/3/3 | 0.9 |
| First surgery (PPV + Scleral buckle/Scleral buckle) | 15/11 | 10/7 | 0.5 |
| Combined surgery with Phaco | 19/7 | 14/3 | 0.3 |
| Localization of RD (superior/inferior/total) | 7/12/7 | 8/6/3 | 0.3 |
| Status of macula, attached/detached, (% of attached macula) |
2/14 (12.5%) | 0/17 (0.0%) | 0.3 |
| PVR Severity, grade (C1/C2/C3/C4) | 0/13/9/4 | 0/4/10/3 | 0.2 |
| Baseline BCVA, LogMAR | 1.58 ± 0.30 | 1.62 ± 0.23 | 0.6 |
| Tamponade (SO/C3F8) | 23/3 | 17/0 | 0.1 |
| Functional Success (BCVA ≥ 1.3 LogMAR at the final visit) (%) | 23.0% | 58.8% | 0.01* |
| Final anatomical Success (%, retinal attachment at the final visit) | 65.4% | 94.1% | 0.03* |
Abbreviations: n, number of patients, RD, retinal detachment, PVR, proliferative vitreoretinopathy, BCVA, best corrected visual acuity, SO, silicone oil, C3F8, perfluoropropane, p, P value. Italic values shows statistically significance, *chi-square test.